Research Topics
Species | M OpravilSummaryAffiliation: University Hospital Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
A randomized trial of interferon-alpha2a and zidovudine versus bleomycin and zidovudine for AIDS-related Kaposi's sarcoma. Swiss HIV Cohort StudyM Opravil
Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland
Int J STD AIDS 10:369-75. 1999..The antiviral activity of interferon-alpha or the chemotherapy-mediated increase in the risk for opportunistic infections may explain these differences...- Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. Swiss HIV Cohort StudyM Opravil
Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland
J Acquir Immune Defic Syndr 23:17-25. 2000..Thus, even if treatment is initiated early in asymptomatic patients with preserved CD4 counts, three drugs are necessary to achieve sustained decreases of HIV load in blood and lymphoid tissue... - A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infectionMilos Opravil
Division of Infectious Diseases, University Hospital, CH 8091 Zurich, Switzerland
J Infect Dis 185:1251-60. 2002.... - Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007Marie Ballif
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
PLoS ONE 4:e8275. 2009..Combination antiretroviral treatment (cART) has been very successful, especially among selected patients in clinical trials. The aim of this study was to describe outcomes of cART on the population level in a large national cohort... - Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort StudyB Ledergerber
Division of Infectious Diseases and Hospital Epidemiology, University of Zurich, Switzerland
Lancet 353:863-8. 1999..The efficacy of highly active antiretroviral therapy (HAART) in suppression of HIV-1 is well documented. We investigated virological and clinical outcomes of HAART in routine practice... - Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infectionL R Bisset
Division of Clinical Immunology, Department of Internal Medicine, University Hospital, Zurich, Switzerland
J Acquir Immune Defic Syndr 27:266-71. 2001..Nevertheless, continued management of T-cell subset recovery is significantly more effective in the presence of completely suppressed viral replication... - Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre studyH Furrer
Division of Infectious Diseases, University of Berne, Switzerland
AIDS 15:501-7. 2001.... - CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapyNina Khanna
Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Basel, Switzerland
Clin Infect Dis 47:1093-101. 2008.... - Trends over time of virological and immunological characteristics in the Swiss HIV Cohort StudyB Ledergerber
Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland
HIV Med 12:279-88. 2011..The long-term outcome of antiretroviral therapy (ART) is not assessed in controlled trials. We aimed to analyse trends in the population effectiveness of ART in the Swiss HIV Cohort Study over the last decade... - Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort StudyR Weber
Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital, Zurich, Raemistrasse 100, Zurich CH 8091, Switzerland
HIV Med 10:407-16. 2009..Design A prospective observational study of all participants in the Swiss HIV Cohort Study followed between 1997 and 2006 was carried out... - Discontinuation of enfuvirtide in heavily pretreated HIV-infected individualsLuigia Elzi
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
HIV Clin Trials 10:207-14. 2009..We aimed to evaluate the efficacy and the impact of discontinuing and/or switching enfuvirtide on virologic and clinical parameters in clinical practice... - Ageing with HIV: medication use and risk for potential drug-drug interactionsCatia Marzolini
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
J Antimicrob Chemother 66:2107-11. 2011..To compare the use of co-medication, the potential drug-drug interactions (PDDIs) and the effect on antiretroviral therapy (ART) tolerability and efficacy in HIV-infected individuals according to age, ? 50 years or <50 years... - Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failurePedram Sendi
Division of Infectious Diseases and Hospital Epidemiology, Basel University Hospital, Basel, Switzerland
PLoS ONE 2:e173. 2007..We estimated the clinical effect, cost and cost-effectiveness of using GRT as compared to expert opinion in patients with antiretroviral treatment failure... - Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort StudyCatia Marzolini
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
Antivir Ther 15:413-23. 2010..We investigated the prevalence of comedications and PDDIs within a large HIV cohort, and their effect on ART efficacy and tolerability... - Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort StudyNina Khanna
Division of Infectious Diseases and Hospital Epidemiology, University Hospital, University of Basel, Basel, Switzerland
Clin Infect Dis 48:1459-66. 2009..We investigated the incidence and outcome of progressive multifocal leukoencephalopathy (PML) in human immunodeficiency virus (HIV)-infected individuals before and after the introduction of combination antiretroviral therapy (cART) in 1996... - Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapyR Speich
Department of Internal Medicine, Zurich University Hospital, Ramistrasse 100, Zurich, CH 8091, Switzerland
Swiss Med Wkly 131:663-5. 2001..The patient remains in excellent health and his sole complaint is of mild dyspnoea on exertion... - Highly sensitive methods for quantitation of human immunodeficiency virus type 1 RNA from plasma, cells, and tissuesM Fischer
Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Zurich, CH 8091 Zurich, Switzerland
J Clin Microbiol 37:1260-4. 1999..These techniques facilitate direct comparisons of viral loads between liquid and cellular specimens. Application of these sensitive methods may improve the assessment of the response to new antiretroviral regimens... - Prediction of HIV-1 RNA suppression and its durability during treatment with zidovudine/lamivudineM Opravil
Division of Infectious Diseases, University Hospital, Zurich, Switzerland
Antivir Ther 3:169-76. 1998..The baseline parameters should influence the choice of the antiretroviral regimen... - Antiretroviral treatment monitoring with an improved HIV-1 p24 antigen test: an inexpensive alternative to tests for viral RNAJ Schupbach
Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
J Med Virol 65:225-32. 2001..5% of those for RNA (P <.0001). These results indicate that heat-denatured, amplification-boosted p24 antigen measurement can be used as a simple and inexpensive alternative to HIV RNA testing for monitoring treatment... - Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected childrenChristoph Rudin
Division of Infectious Diseases, University Children s Hospital, Basel, Switzerland
Pediatr Infect Dis J 27:431-7. 2008..To evaluate the long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced, initially protease inhibitor (PI)-naive, human immunodeficiency virus (HIV)-1-infected children... - A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumoniaB Hirschel
Division of Infectious Diseases, , Geneva, Switzerland
N Engl J Med 324:1079-83. 1991..5 percent) to discontinue taking it. CONCLUSIONS. A dose of 300 mg of aerosolized pentamidine given every four weeks was well tolerated and 60 to 70 percent effective in preventing a first episode of PCP in patients with HIV infection... - Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patientsM Opravil
Department of Medicine, University Hospital, , Switzerland
Clin Exp Immunol 84:185-9. 1991..5 micrograms/ml), confirming a particularly low vaccination response in patients who were severely immunocompromised... - HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapyAndri Rauch
Division of Infectious Diseases, University Hospital Bern and University of Bern, Switzerland
Clin Infect Dis 46:1921-5. 2008..01, compared with HLA-Bw4 homozygotes). HLA-Bw4 homozygosity appears to predict an impaired CD4 T cell recovery after initiation of combination antiretroviral therapy... - Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapyM Fischer
Department of Internal Medicine, University Hospital Zurich, Switzerland
AIDS Res Hum Retroviruses 16:1135-40. 2000..69; p = 0.003). These findings support the concept that measurement of HIV-1 RNA in the easily accessible PBMC compartment is relevant for evaluating the potency of current and future antiretroviral therapies... - Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infectionH Kuster
Department of Internal Medicine, University Hospital Zurich, Switzerland
Am J Pathol 156:1973-86. 2000..Thus, full and sustained suppression of viral replication was required to efficiently decrease viral load in lymphoid tissue, but complete abolition of residual viral replication was not achieved... - Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapyS Bertschy
Division of Infectious Diseases, University Hospital Berne, Bern, Switzerland
Clin Microbiol Infect 12:666-71. 2006..Patients who remain clinically and radiologically free of relapse at 6 months after discontinuation are unlikely to experience a relapse of TE... - Enteric infections and diarrhea in human immunodeficiency virus-infected persons: prospective community-based cohort study. Swiss HIV Cohort StudyR Weber
Department of Medicine, University Hospital, Zurich, Switzerland
Arch Intern Med 159:1473-80. 1999..We studied (1) the epidemiology of enteric pathogens associated with diarrhea, (2) the diagnostic yield of stool examination and endoscopic evaluation, (3) risks to develop diarrhea, and (4) the impact of diarrhea on patients' survival... - Long-term survival and interruption of HAART in HIV-related pulmonary hypertensionA S Zinkernagel
Division of Infectious Diseases, Department of Medicine, University Hospital, RAE U 74, , 8091 Zurich, Switzerland
Eur J Clin Microbiol Infect Dis 24:153-5. 2005..In cases in which HAART is associated with relevant toxicity, interruption of HAART in patients with PAHRH can be considered, but should be used only if no alternatives are available. Close follow-up is warranted... - Monitoring of co-trimoxazole concentrations in serum during treatment of pneumocystis carinii pneumoniaB Joos
Division of Infectious Diseases, University Hospital, , Switzerland
Antimicrob Agents Chemother 39:2661-6. 1995.... - CCTTT-repeat polymorphism of the inducible nitric oxide synthase is not associated with HIV pathogenesisM Hersberger
Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland
Clin Exp Immunol 137:566-9. 2004..Regulation of iNOS expression by the functional CCTTT-polymorphism does not modify HIV pathogenesis... - Alveolar echinococcosis of the liver in an adult with human immunodeficiency virus type-1 infectionW Zingg
Division of Infectious Diseases and Hospital Epidemiology, Dept of Internal Medicine, University Hospital of Zurich, CH 8og91 Zurich, Switzerland
Infection 32:299-302. 2004..These observations suggest that the benzimidazoles, albendazole and mebendazole, may interact with protease inhibitors, which are known for their strong inhibition of the CYP3A4... - Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cellsG A Funk
Department of Theoretical and Computational Biology, Friedrich Miescher Institute, Basel, Switzerland
J Acquir Immune Defic Syndr 26:397-404. 2001..03 and R0(pers) approximately 0.008, respectively) indicating that these compartments contribute little to the total basic reproductive rate and cannot maintain an ongoing infection in absence of actively infected cells... - Subgroup and resistance analyses of raltegravir for resistant HIV-1 infectionDavid A Cooper
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney
N Engl J Med 359:355-65. 2008.... - Raltegravir with optimized background therapy for resistant HIV-1 infectionRoy T Steigbigel
State University of New York at Stony Brook, Stony Brook, USA
N Engl J Med 359:339-54. 2008..Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs... - The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavirSara Colombo
Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
J Infect Dis 198:864-7. 2008..2%, respectively; P < .0001). Therefore, HCP5 genotyping could serve as a simple screening tool for ABC-HSR, particularly in settings where sequence-based HLA typing is not available... - Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistenceM C Strain
Department of Medicine and Pathology, University of California at San Diego, La Jolla, CA 90293, USA
Proc Natl Acad Sci U S A 100:4819-24. 2003..Eradication will not be achieved with complete inhibition of viral replication alone... - Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort StudyK Boubaker
University Hospital of Lausanne, 1011 Lausanne, Switzerland
Clin Infect Dis 33:1931-7. 2001..Age, sex, or stage of infection with human immunodeficiency virus were not predictive of hyperlactatemia. Determination of lactate levels may prove useful in the screening for mitochondrial toxicity... - Updated European recommendations for the clinical use of HIV drug resistance testingA M Vandamme
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
Antivir Ther 9:829-48. 2004..The panel also encourages the timely collection of epidemiological information to estimate the impact of transmission of resistant HIV and the prevalence of HIV-1 non-B subtypes in the different European countries... - Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland comparedOlivia Keiser
Institute of Social and Preventive Medicine ISPM, University of Bern, Bern, Switzerland
PLoS Med 5:e148. 2008..We compared virologic response, changes to first-line regimens, and mortality in HIV-infected patients starting HAART in South Africa and Switzerland... - Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort StudyThi Tuyet Nhung Vo
VCHAP Project, Tropical Disease Hospital, Ho Chi Minh City, Vietnam
J Infect Dis 197:1685-94. 2008..Little is known about time trends, predictors, and consequences of changes made to antiretroviral therapy (ART) regimens early after patients initially start treatment... - Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarctionC A Sabin
Dept of Primary Care and Population Sciences, Royal Free and UC Medical School, Rowland Hill St, London, NW3 2PF, United Kingdom
Clin Infect Dis 46:1101-10. 2008..We evaluated changes in risk factors for CVD and the use of lipid-lowering therapy in HIV-infected individuals and assessed the impact of any changes on the incidence of myocardial infarction... - Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaborationCaroline A Sabin
Lancet 371:1417-26. 2008..The excess risk does not seem to be explained by underlying established cardiovascular risk factors and was not present beyond 6 months after drug cessation...